Cargando…
Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial
BACKGROUND: The propagation of prions, the causative agents of Creutzfeldt-Jakob disease and other human prion diseases, requires post-translational conversion of normal cellular prion protein to disease-associated forms. The antimalarial drug quinacrine (mepacrine) prevents this conversion in vitro...
Autores principales: | Collinge, John, Gorham, Michele, Hudson, Fleur, Kennedy, Angus, Keogh, Geraldine, Pal, Suvankar, Rossor, Martin, Rudge, Peter, Siddique, Durre, Spyer, Moira, Thomas, Dafydd, Walker, Sarah, Webb, Tom, Wroe, Steve, Darbyshire, Janet |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Lancet Pub. Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2660392/ https://www.ncbi.nlm.nih.gov/pubmed/19278902 http://dx.doi.org/10.1016/S1474-4422(09)70049-3 |
Ejemplares similares
-
Video Rating in Neurodegenerative Disease Clinical Trials: The Experience of PRION-1
por: Carswell, Christopher, et al.
Publicado: (2012) -
Pharmacokinetics of quinacrine in the treatment of prion disease
por: Yung, Lotus, et al.
Publicado: (2004) -
Comparative Genome Analysis and Gene Finding in Candida Species Using CGOB
por: Maguire, Sarah L., et al.
Publicado: (2013) -
Limited Evolutionary Conservation of the Phenotypic Effects of Antibiotic Resistance Mutations
por: Apjok, Gábor, et al.
Publicado: (2019) -
Continuous Quinacrine Treatment Results in the Formation of Drug-Resistant Prions
por: Ghaemmaghami, Sina, et al.
Publicado: (2009)